Evaluation of the efficacy of photodynamic antimicrobial therapy using a phenothiazine compound and LED (red-orange) on the interface: macrophage vs S. aureus

Antimicrobial Photodynamic therapy is a technique in which microorganisms are exposed to a photosensitizing drug and then irradiated with low-intensity visible light of the appropriate wavelength. The resulting photochemical reaction generates cytotoxic reactive oxygen species, such as singlet oxygen and free radicals, which are able to exert bactericidal effect. Much is already known about the photodynamic inactivation of microorganisms: both antibiotic-sensitive and resistant strains can be successfully photo inactivated, and there is the additional advantage that repeated photosensitization of bacterial cells does not induce a selection of resistant strains. Recently, a series of studies have shown that it is possible to kill bacteria with a light source after the microorganisms have been sensitized with low concentration of dye, such as phenothiazines. The aim of this study was to evaluate the phagocytic function of macrophages J774 against S. aureus in the presence and absence of AmPDT with phenothiazine compound (12.5 μg/mL) and red-orange LED. Experimental groups: Control Group (L-F-), Phenothiazine group (L-F+) LED group (L+F-), Photodynamic therapy group (L+F+). The tests presented in this study were carried out in triplicate. This study demonstrated that AmPDT is able to increase about twice the phagocytic ability of macrophages; however, the bactericidal capacity of these cells did not show a substantial improvement, probably because the oxidative burst was less intense.

[1]  A. Benenson Control of communicable diseases manual , 1995 .

[2]  A. Tomasz,et al.  Antibiotic resistant Staphylococcus aureus: a paradigm of adaptive power. , 2007, Current opinion in microbiology.

[3]  R. Skov,et al.  Epidemiology of Emerging Methicillin-Resistant Staphylococcus aureus (MRSA) in Denmark: a Nationwide Study in a Country with Low Prevalence of MRSA Infection , 2005, Journal of Clinical Microbiology.

[4]  Antônio L. B. Pinheiro,et al.  Photodynamic antimicrobial chemotherapy (PACT) using phenothiazines derivatives associated with the red laser against staphylococcus aureus , 2013, Photonics West - Biomedical Optics.

[5]  Katherine O'Riordan,et al.  Staphylococcus aureus Capsular Polysaccharides , 2004, Clinical Microbiology Reviews.

[6]  M. Wainwright The development of phenothiazinium photosensitisers. , 2005, Photodiagnosis and photodynamic therapy.

[7]  J. Cole,et al.  The role of macrophages in the innate immune response to Streptococcus pneumoniae and Staphylococcus aureus: mechanisms and contrasts. , 2014, Advances in microbial physiology.

[8]  P. A. Wright,et al.  Photobactericidal activity of phenothiazinium dyes against methicillin-resistant strains of Staphylococcus aureus. , 1998, FEMS microbiology letters.

[9]  Carol Kim,et al.  Development of a respiratory burst assay using zebrafish kidneys and embryos. , 2004, Journal of immunological methods.

[10]  Antônio L. B. Pinheiro,et al.  Photodynamic antimicrobial chemotherapy (PACT) using phenothiazines derivatives associated with the red-orange LED against staphylococcus aureus , 2013, Photonics West - Biomedical Optics.

[11]  Giulio Jori,et al.  Photoinactivation of bacterial strains involved in periodontal diseases sensitized by porphycene–polylysine conjugates , 2002, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[12]  L. Lutz,et al.  Clinical failure of vancomycin treatment of Staphylococcus aureus infection in a tertiary care hospital in southern Brazil. , 2003, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[13]  J. Potempa,et al.  The Janus Face of a-Toxin: A Potent Mediator of Cytoprotection in Staphylococci-Infected Macrophages , 2014, Journal of Innate Immunity.

[14]  G. A. Oliveira,et al.  Avaliação da tolerância à vancomicina em 395 cepas hospitalares de Staphylococcus aureus resistentes à oxacilina , 2001 .